Filing Analysis
Outset Medical, Inc. announced that General Counsel John Brottem will depart the company on September 11, 2026, to pursue other professional opportunities. The departure is stated to be amicable and not due to any disagreement with the company or its management.
📋 Key Facts
- Officer: John Brottem
- Position: General Counsel
- Departure Date: September 11, 2026
- Reason for departure: To pursue other professional opportunities
- Dispute status: No dispute or disagreement with the Company or its management reported
Outset Medical, Inc. announced its second quarter 2026 financial results via a press release on August 6, 2026. The filing serves as the formal notification of the earnings announcement.
📋 Key Facts
- Reporting period: Second Quarter 2026 ended June 30, 2026.
- Announcement date: August 6, 2026.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Outset Medical entered into a 'Refresh Amendment' with HCA Management Services, L.P. to update HCA's existing fleet of Tablo Hemodialysis Systems with new units between 2026 and 2028.
📋 Key Facts
- Aggregate contract value for the refresh is approximately $40 million, net of rebates and allowances.
- The agreement spans from 2026 through the end of 2028.
- The amendment includes a framework for console and consumables purchases to support future growth within HCA hospitals.
- The company is reiterating its previously issued 2026 guidance.
Outset Medical reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. The company successfully elected two Class III directors, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as its independent auditor.
📋 Key Facts
- Annual Meeting held on June 4, 2026, with a quorum of 13,890,864 shares present out of 18,529,233 outstanding.
- Brent D. Lang and Karen Prange were elected as Class III directors for terms ending in 2029.
- The 2025 compensation for named executive officers was approved on a non-binding advisory basis (7,548,774 For vs 3,196,870 Against).
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Outset Medical, Inc. announced that Marc Nash, Executive Vice President of R&D, Operations and Service, will depart the company effective June 5, 2026, to pursue other professional opportunities.
🚩 Red Flags
- Loss of a key executive overseeing three critical functions simultaneously: R&D, Operations, and Service
📋 Key Facts
- Executive departing: Marc Nash
- Role: Executive Vice President, R&D, Operations and Service
- Departure date: June 5, 2026
- Reason provided: To pursue other professional opportunities
- Company states the departure is not due to any dispute or disagreement with management
Outset Medical, Inc. announced its financial results for the first quarter ended March 31, 2026. The company furnished a press release and scheduled an earnings conference call to discuss the results.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026.
- The report was filed on May 7, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release titled 'Outset Medical Reports First-Quarter Results' was included as Exhibit 99.1.
- The report was signed by Renee Gaeta, Chief Financial Officer.
Outset Medical, Inc. announced its fourth quarter and full year 2025 financial results on February 11, 2026. The company also provided revenue and non-GAAP gross margin guidance for the fiscal year 2026.
🚩 Red Flags
- None identified in the text of this specific filing (standard forward-looking statement warnings included).
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2025.
- Announcement date: February 11, 2026.
- Company provided 2026 revenue guidance.
- Company provided 2026 non-GAAP gross margin guidance.
Outset Medical announced that the FDA has granted 510(k) clearance for its next-generation Tablo platform. The company expects to begin shipping this new technology to customers in Q2 2026.
📋 Key Facts
- FDA granted 510(k) clearance for the next-generation Tablo platform on January 27, 2026.
- Product shipping is expected to commence in the second quarter of 2026.
- The announcement was made via an Item 8.01 'Other Events' filing.
Outset Medical, Inc. announced the resignation of Board Director Andrea Saia and the appointment of Karen Prange to fill her vacancy. The company also issued preliminary unaudited revenue results for Q4 and FY 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Andrea Saia resigned from the Board effective January 9, 2026; resignation was not due to any disagreement with the Company.
- Karen Prange appointed as a new Director and member of the Compensation Committee, effective January 9, 2026.
- Ms. Prange is an independent director with extensive medical device leadership experience (formerly Boston Scientific, Henry Schein, Johnson & Johnson).
- The company issued preliminary, unaudited revenue results for Q4 and FY 2025 via press release on January 12, 2026.
- Ms. Prange will receive an initial equity grant of 18,667 RSUs vesting quarterly over three years.
Outset Medical, Inc. announced its third quarter 2025 financial results and issued revised revenue guidance for the full fiscal year 2025.
🚩 Red Flags
- Revision of full-year revenue guidance often indicates a miss in previous projections or changing market conditions.
- Forward-looking statements explicitly mention risks regarding 'cash burn', 'cash position', and the 'sufficiency of the Company’s cash balances through cashflow breakeven'.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025.
- Announcement date: November 10, 2025.
- The company is providing revised financial guidance for its 2025 revenue.
- Management is focusing on cost reduction actions and optimizing the commercial organization.
Outset Medical, Inc. announced its second quarter 2025 financial results and provided updated revenue guidance for the full year 2025. The company's press release highlights momentum in revenue growth, console placements, and utilization.
🚩 Red Flags
- Forward-looking statements include risks regarding the sufficiency of cash balances through cashflow breakeven, indicating potential liquidity monitoring is ongoing.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Announcement date: August 6, 2025.
- The filing includes updated financial guidance for 2025 revenue.
- Management highlighted 'strong revenue growth' and increased utilization of their Tablo platform.
Outset Medical, Inc. announced the appointment of Renee Gaeta as new CFO and Principal Financial/Accounting Officer, effective June 3, 2025. This follows the departure of former CFO Nabeel Ahmed to pursue other opportunities.
🚩 Red Flags
- Executive turnover (CFO departure) can sometimes signal internal friction, though the company explicitly denies any disagreement regarding financial operations.
📋 Key Facts
- Renee Gaeta appointed CFO, PFO, and PAO effective June 3, 2025.
- Gaeta's compensation includes a $500,000 base salary and an RSU award valued at $2,480,000.
- Nabeel Ahmed is departing to pursue other opportunities; his departure is not related to any disagreements with the company or its auditors.
- Ahmed will receive 9 months of severance (lump sum salary + COBRA).
- Annual Meeting results: Election of Class II Directors and ratification of KPMG LLP as independent auditor were approved.
Outset Medical, Inc. announced the resignation of Director Dale E. Jones and the appointment of industry veteran Kevin O’Boyle to the Board and as Chair of the Audit Committee, effective May 14, 2025.
🚩 Red Flags
- None identified; resignation was explicitly stated as not being due to disagreements regarding operations, policies, or practices.
📋 Key Facts
- Dale E. Jones resigned from the Board on May 10, 2025, effective May 14, 2025; resignation was not due to any disagreement with the company.
- Kevin O’Boyle appointed as a new Director and Chair of the Audit Committee, effective May 14, 2025.
- O'Boyle is designated as an 'audit committee financial expert'.
- Patrick T. Hackett transitioned out of the Audit Committee Chair role to make way for O'Boyle.
- Andrea Saia moved from the Audit Committee to the Compensation Committee; D. Keith Grossman appointed Compensation Committee Chair.
Outset Medical, Inc. announced its first quarter 2025 financial results via a press release on May 7, 2025. The filing serves as a formal notice of the earnings announcement and includes an exhibit detailing quarterly performance.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Report date: May 7, 2025
- Company reported 'Strong Growth' in Console and Recurring Revenue according to the press release title
- Key performance indicators mentioned include expanded Gross Margin and declined Cash Use
- Exhibit 99.1 contains the full earnings press release
Outset Medical, Inc. has implemented a one-for-fifteen reverse stock split effective March 20, 2025. This action follows stockholder approval from a special meeting held on March 5, 2025.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements or avoid delisting).
📋 Key Facts
- Reverse stock split ratio: 1-for-15
- Effective date: March 20, 2025, at 12:01 a.m. ET
- New CUSIP number: 690145206
- No fractional shares will be issued; instead, stockholders receive cash in lieu of fractions based on the closing price from the last trading day prior to effectiveness.
- The split was authorized by stockholders on March 5, 2025.
Outset Medical, Inc. has announced a 1-for-15 reverse stock split to be effective March 20, 2025. This action will consolidate shares and adjust the trading price of the common stock.
🚩 Red Flags
- Reverse stock split (often used to avoid Nasdaq delisting due to low share price).
📋 Key Facts
- Reverse stock split ratio is 1-for-15.
- Effective date: March 20, 2025, at 12:01 a.m. ET.
- Shares will begin trading on a split-adjusted basis at market open on March 20, 2025.
- Fractional shares will be settled in cash based on the closing price from the last trading day prior to effectiveness.
- Proportionate adjustments will apply to outstanding equity awards and incentive plans.
Outset Medical issued Series A Non-Voting Convertible Preferred Stock to directors, officers, and employees following stockholder approval. This was followed by a massive conversion of preferred shares into common stock, significantly increasing the total outstanding share count.
🚩 Red Flags
- Significant dilution: The conversion added over 210 million common shares to the float, drastically increasing the total share count.
- Related-party issuance: Shares were issued directly to directors, officers, and employees.
- Scrivener's error in preferred stock terms regarding mathematical formulas for conversion/rights.
📋 Key Facts
- On March 7, 2025, the Company issued 19,432 shares of Series A Preferred Stock to directors, officers, and employees.
- On March 10, 2025, 842,753 shares of Series A Preferred Stock converted into 210,688,250 shares of common stock.
- Post-conversion total outstanding common stock is 265,493,926 shares.
- A Certificate of Correction was filed to fix a mathematical formula error (numerator vs. denominator) in the Series A Preferred Stock designation.
Outset Medical, Inc. held a Special Meeting of Stockholders on March 5, 2025, where shareholders approved several critical proposals, including a reverse stock split and the issuance of preferred stock to comply with Nasdaq rules.
🚩 Red Flags
- Reverse stock split approved (1-for-10 to 1-for-15 ratio), typically used to boost share price to meet minimum Nasdaq listing requirements.
- Approval of issuance of preferred stock at less than 'minimum price' and potential 'change of control' under Nasdaq Rule 5635(b).
- Issuance of equity to insiders (directors, officers, employees) requires specific regulatory compliance/approval.
📋 Key Facts
- Special Meeting held on March 5, 2025; quorum was present with 33,254,357 shares represented.
- Proposal One: Approval for issuance/conversion of Series A Non-Voting Convertible Preferred Stock (up to 20% of outstanding common stock) to comply with Nasdaq Listing Rule 5635. Approved (14,821,054 For).
- Proposal Two: Approval to issue Series A Non-Voting Convertible Preferred Stock to directors, officers, and employees per Nasdaq Listing Rule 5635(c). Approved (14,654,560 For).
- Proposal Three: Approval of a reverse stock split with a ratio between 1-for-10 and 1-for-15, to be determined by the Board within one year. Approved (28,379,878 For).
- Proposal Four: Approval to adjourn the meeting if necessary to solicit additional proxies. Approved.
Outset Medical, Inc. received a second notice from Nasdaq on February 24, 2025, for failing to meet the minimum bid price requirement of $1.00 per share. The company has been granted a 180-day compliance period ending August 25, 2025.
🚩 Red Flags
- Repeated failure to maintain minimum bid price requirement (second notice received).
- Potential for delisting if compliance is not met by August 25, 2025.
- Proposed reverse stock split (1-for-10 to 1-for-15) to artificially boost share price.
📋 Key Facts
- Received second Nasdaq notice on February 24, 2025, for failure to comply with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- Initial compliance period granted until August 25, 2025.
- Stock must maintain a closing bid price of at least $1.00 for 10 consecutive trading days to regain compliance.
- A special meeting of stockholders is scheduled for March 5, 2025, to vote on a potential reverse stock split (ratio between 1-for-10 and 1-for-15).
- Audited financial statements for the years ended December 31, 2024, and 2023 are being filed as Exhibit 99.1.
Outset Medical, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing includes guidance for 2025 revenue and non-GAAP gross margin.
📋 Key Facts
- Announced Q4 and Full Year 2024 financial results on February 19, 2025.
- Provided 2025 guidance for revenue and non-GAAP gross margin.
- Scheduled a fourth quarter and full year 2024 earnings conference call.
Outset Medical, Inc. has adopted an amendment to its Bylaws regarding voting requirements for stockholder meetings. The change shifts the threshold for certain matters from a majority of total voting power present at a meeting to a majority of votes cast.
🚩 Red Flags
- None identified; this is a technical governance change.
📋 Key Facts
- Amendment No. 1 to Amended and Restated Bylaws was adopted on January 23, 2025.
- The amendment changes the voting threshold for matters other than director elections.
- Previous standard: Affirmative vote of a majority of the voting power of capital stock present in person or by proxy.
- New standard: Affirmative vote of a majority of the votes cast at such meeting (unless otherwise provided by law/charter).
Outset Medical, Inc. completed a significant restructuring of its debt and capital structure involving a $100 million term loan from Perceptive Credit Holdings IV, LP and a private placement of Series A Non-Voting Convertible Preferred Stock. The company used the new loan proceeds to repay existing senior secured credit facilities with SLR Investment Corp. and Gemino Healthcare Finance, LLC.
🚩 Red Flags
- Significant dilution risk via warrants (5.6M shares at $0.80) and convertible preferred stock (conversion ratio of 1:250).
- High-cost debt structure involving significant equity warrants for the lender.
- Series A Preferred Stock has a liquidation preference senior to common stock until conversion is approved.
- Potential 'death spiral' characteristics due to the high conversion ratio and dividend escalators on preferred stock.
📋 Key Facts
- Closed a $100 million term loan from Perceptive Credit Holdings IV, LP on January 8, 2025.
- Issued 863,340 shares of Series A Non-Voting Convertible Preferred Stock at $200.00 per share via private placement to various investors, including management and Board members.
- The new loan includes a warrant to purchase 5,625,000 shares of common stock at an exercise price of $0.80.
- Series A Preferred Stock features an 8% annual dividend rate (compounded annually) that increases by 2% if conversion approval is not obtained within six months.
- The company granted a security interest in substantially all assets, including intellectual property, to the new lender.
- Repaid and terminated two existing senior secured credit facilities with SLR Investment Corp. and Gemino Healthcare Finance, LLC.
Outset Medical announced a massive $172.7 million private placement of Series A Non-Voting Convertible Preferred Stock and a new $125 million senior secured credit facility. The financing involves significant potential dilution, with pro forma common shares expected to increase from ~53 million to ~269 million.
🚩 Red Flags
- Extreme dilution: Pro forma share count increases from ~53 million to ~269 million shares upon conversion of preferred stock.
- Significant debt burden: New $125M senior secured facility with a high interest rate (SOFR + 8.0% plus PIK component).
- Restrictive covenants: Debt includes revenue milestones and minimum cash requirements that could trigger default.
- Insider involvement: Management and Directors are participating in the private placement, which requires specific stockholder approval.
📋 Key Facts
- Private placement of 863,340 shares of Series A Non-Voting Convertible Preferred Stock at $200.00 per share.
- Total aggregate proceeds from equity offering: ~$172.7 million ($168.8M from institutional investors; $3.9M from management/directors).
- New senior secured credit facility of up to $125 million (comprising a $100M initial term loan and a $25M delayed draw term loan) with Perceptive Credit Holdings IV, LP.
- The equity offering is subject to stockholder approval on March 5, 2025, regarding conversion terms and director issuance.
- Pro forma common stock outstanding expected to reach ~268.7 million shares upon full conversion (a nearly 5x increase from current levels).
- New debt includes a PIK (payment-in-kind) component of 1.50% per annum for the first two years.
- Credit agreement includes financial covenants: minimum $10M cash balance and specific TTM net revenue targets.
Outset Medical, Inc. announced its third quarter 2024 financial results and provided updated guidance for the full year 2024 regarding revenue and non-GAAP gross margin.
🚩 Red Flags
- None identified in the text of this specific filing.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 6, 2024
- The company issued updated financial guidance for 2024 revenue and non-GAAP gross margin.
- Results were released via press release (Exhibit 99.1).
Outset Medical, Inc. received a notice from Nasdaq stating it is no longer in compliance with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive trading days. The company has been granted an initial 180-day period to regain compliance.
🚩 Red Flags
- Delisting notice (minimum bid price deficiency)
- Stock price performance has been consistently below $1.00
- Risk of being downgraded from Nasdaq Global Select Market to Nasdaq Capital Market or total delisting
📋 Key Facts
- Received notice on September 23, 2024, from Nasdaq Listing Qualifications staff.
- Non-compliance due to closing bid price falling below $1.00 for 30 consecutive trading days (Nasdaq Listing Rule 5450(a)(1)).
- Initial compliance period of 180 days, expiring March 24, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive trading days before the deadline.
- Potential for an additional 180-day period to transfer listing to Nasdaq Capital Market if requirements are met.
Jim Hinrichs resigned from the Board and as Audit Committee Chair effective August 15, 2024. The resignation is due to a new affiliation with Baxter International's Vantive spin-off and not due to any disagreement with Outset Medical.
🚩 Red Flags
- None identified; company explicitly states the resignation is not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Jim Hinrichs resigned from the Board and Audit Committee Chair role on August 15, 2024.
- Resignation is linked to a significant affiliation with Vantive (Baxter International's kidney care spin-off).
- The Board size was reduced from eight directors to seven directors.
- Patrick T. Hackett appointed as new Audit Committee Chair; identified as an 'audit committee financial expert'.
- Karen Drexler transitioned to Nominating and Corporate Governance Committee Chair.
Outset Medical, Inc. announced its second quarter 2024 financial results and provided updated financial guidance for the full year 2024 regarding revenue and non-GAAP gross margin.
🚩 Red Flags
- Management mentions 'cost reduction actions' and 'restructurings' in forward-looking statements, which may indicate pressure on operating margins or cash flow.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 7, 2024.
- Company issued updated financial guidance for 2024 revenue and non-GAAP gross margin.
- The filing includes a press release (Exhibit 99.1) detailing the results.
Outset Medical, Inc. held its Annual Meeting of Stockholders on May 29, 2024. The meeting resulted in the election of three Class I directors and the ratification of KPMG LLP as the independent auditor.
🚩 Red Flags
- Significant opposition to executive compensation: Proposal Two received approximately 48% of 'For' votes vs. 47% of 'Against' votes (excluding abstentions/broker non-votes), indicating substantial shareholder dissatisfaction with pay structures.
📋 Key Facts
- Annual Meeting held on May 29, 2024, via virtual webcast.
- Quorum was present with 38,482,261 shares represented out of 51,702,159 outstanding shares.
- Karen Drexler, Dale E. Jones, and Leslie Trigg were elected to the Board as Class I directors until 2027.
- Stockholders approved the 2023 compensation for named executive officers (Say-on-Pay) with a significant number of 'Against' votes (16,462,009).
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Outset Medical, Inc. announced the departure of its Chief Technology Officer, Jean-Olivier Racine, effective May 17, 2024, as part of a broader workforce reduction plan. The company also reported restructuring charges of $3.0 million related to these organizational changes.
🚩 Red Flags
- Departure of a C-suite officer (CTO) in conjunction with a workforce reduction plan.
- Restructuring charges indicate cost-cutting measures to improve operational efficiency.
📋 Key Facts
- CTO Jean-Olivier Racine departing effective May 17, 2024.
- Departure is linked to a workforce reduction plan implemented in May 2024.
- Company recognized $3.0 million in restructuring charges for Q1 2024 for severance and termination benefits.
- Severance package includes nine months of base salary and COBRA premiums.
- Accelerated vesting of 33,923 restricted stock units (RSUs) approved for the departing CTO.
Outset Medical announced that the FDA has granted 510(k) clearance for its TabloCart with Prefiltration. The company has resumed distribution of this product and reports it is ready to ship to U.S. customers.
📋 Key Facts
- FDA granted 510(k) clearance for TabloCart with Prefiltration on May 6, 2024.
- The company has officially resumed distribution of the cleared product.
- Product is currently available to ship to customers in the United States.
Outset Medical announced the resignation of Board member Catherine Szyman and the appointment of medical technology veteran Brent D. Lang to the Board and Audit Committee.
🚩 Red Flags
- None identified; resignation is amicable and related to an external career opportunity.
📋 Key Facts
- Catherine Szyman resigned from the Board effective March 12, 2024, to assume the CEO role at an Edwards Lifesciences spinoff.
- The company stated Ms. Szyman's resignation is not due to any disagreement regarding operations, policies, or practices.
- Brent D. Lang was appointed to the Board and Audit Committee effective March 12, 2024.
- Mr. Lang previously served as CEO of Vocera Communications, Inc., which was acquired by Stryker Corporation in 2022.
- The appointment is for a Class III director term expiring at the 2026 annual meeting.
Outset Medical, Inc. announced the departure of its Chief Commercial Officer, Steve Williamson, effective March 1, 2024. The company also issued a press release regarding its Q4 and full year 2023 financial results.
🚩 Red Flags
- Loss of a key executive (Chief Commercial Officer) in the middle of fiscal reporting period.
📋 Key Facts
- Steve Williamson is departing as Chief Commercial Officer on March 1, 2024.
- The departure is to assume the CEO role at another publicly traded medical device company.
- The Company stated the departure is not due to any dispute or disagreement with management.
- Financial results for the quarter and year ended December 31, 2023, were released via press release.
Outset Medical, Inc. issued an 8-K to announce preliminary unaudited revenue results for Q4 and FY2023, alongside providing financial guidance for the full year 2024.
🚩 Red Flags
- Financial results are preliminary and unaudited, meaning they are subject to change upon completion of audits.
📋 Key Facts
- Company announced expected revenue for Q4 and fiscal year ended December 31, 2023.
- Provided 2024 revenue guidance and non-GAAP gross margin guidance.
- The financial information provided is preliminary, unaudited, and subject to adjustment during the year-end closing process.
- Company participated in or prepared for the J.P. Morgan Healthcare Conference.
Outset Medical, Inc. announced the borrowing of approximately $66.5 million in term loans on January 2, 2024, under its existing SLR Term Loan Facility. This follows a previous borrowing on December 11, 2023, bringing the total outstanding principal to $200.0 million.
🚩 Red Flags
- Increased debt load: The company has rapidly increased its leverage, with two significant borrowings in less than one month (Dec 11 and Jan 2).
📋 Key Facts
- Borrowed and received approximately $66.5 million in term loans on January 2, 2024.
- Borrowing was conducted under an existing SLR Term Loan Facility with SLR Investment Corp. as collateral agent.
- Total outstanding principal amount of the SLR Term Loan Facility is now $200.0 million following this and a previous borrowing on December 11, 2023.